

WHAT IS CLAIMED AS NEW AND DESIRED TO BE SECURED BY LETTERS  
PATENT OF THE UNITED STATES IS:

1. A peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell,  
5 said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.

2. The peptide of Claim 1, wherein the HLA molecule is HLA-A31.

10 3. The peptide of Claim 1, wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.

15 4. The peptide of Claim 1, which has an amino-acid sequence obtained by modifying the amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing in order that said peptide can induce more efficiently the cytotoxic T cell that targets the gastric cancer cell.

20 5. The peptide of claim 4 which has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.

25 6. A composition for preventing or treating human gastric cancer, said composition containing a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets the gastric cancer cell.

7. The composition of Claim 6, wherein the HLA molecule is HLA-A31.

8. The composition of Claim 6, wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of  
5 the Sequence Listing.

9. The composition of Claim 6, wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.

10. A DNA encoding a peptide which is a fragment of a  
10 gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.

11. The DNA of Claim 10, wherein the HLA molecule is  
15 HLA-A31.

12. The DNA of Claim 10, wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.

13. The DNA of claim 10, wherein said peptide has an  
20 amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.

14. A vaccine for preventing or treating human gastric cancer, said vaccine containing a recombinant virus or a recombinant bacterium having a DNA encoding a peptide  
25 which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being

bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.

15. The vaccine of Claim 14, wherein the HLA molecule is HLA-A31.

5        16. The vaccine of Claim 14, wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 1 of the Sequence Listing.

10       17. The vaccine of claim 14, wherein said peptide has an amino-acid sequence represented by SEQ ID NO: 2 of the Sequence Listing.

15       18. A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.

20       19. A method for preventing or treating gastric cancer comprising administering to a patient in need thereof an effective amount of CTL which have been activated with a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell, said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.

25       20. A method for preventing or treating gastric cancer, comprising administering to a patient in need

thereof an effective amount of a vaccine containing a recombinant virus or a recombinant bacterium having a DNA encoding a peptide which is a fragment of a gastric cancer antigen protein present in a human gastric cancer cell,  
5 said fragment being bound to an HLA molecule and capable of inducing a cytotoxic T cell that targets said gastric cancer cell.